Clinical trials: Disorder, Mood
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder.
- Trial name
- RELIANCE-II (NCT04855747)
- Testing
- REL-1017
- Where
- 70 sites in United States
- Volunteers
- 236 people
- Sponsor
- Levomecor Inc.
Depressive Disorder, Major
Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)
The study will evaluate the efficacy, safety, and tolerability of 225 milligrams (mg) and 450 milligrams (mg) of Rapastinel, compared to placebo in participants with major depressive disorder (MDD).
- Trial name
- NCT03675776
- Testing
- Rapastinel
- Where
- 23 sites in Hungary, Japan and 3 more
- Volunteers
- 50 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Major Depressive Disorder
5-HTP and Creatine for Depression
This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression.
- Trial name
- NCT04395183
- Testing
- 5-Hydroxytryptophan 100 MG, Creatine monohydrate
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Utah
Major Depressive Disorder, Post-Traumatic Stress Disorder (PTSD)
PET Imaging of mGLuR5 With Drug Challenge
This study is designed to look at that involvement of a process in the brain called the glutamate system in depression. Participants will undergo a screening session, up to two functional Magnetic Resonance Imaging (fMRI) scans…
- Trial name
- NCT01691092
- Testing
- Ketamine
- Where
- 3 sites in United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Yale University
Treatment Resistant Depression
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
The Safety and Efficacy of Psilocybin as an Adjunctive Therapy in Participants with Treatment-Resistant Depression
- Trial name
- NCT04739865
- Testing
- Psilocybin
- Where
- 2 sites in United States, Ireland
- Volunteers
- 19 people
- Sponsor
- COMPASS Pathways
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01180400
- Testing
- TC-5214
- Where
- 66 sites in Czechia, Estonia and 8 more
- Volunteers
- 295 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizo Affective Disorder
D-serine Augmentation of Neuroplasticity
Schizophrenia is a major public health problem associated with cognitive deficits, such as short and long term memory, executive functioning, attention and speed of processing that are amongst the strongest predictors of impaired…
- Trial name
- NCT03711500
- Testing
- D-serine
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- New York State Psychiatric Institute
Bipolar Depression, Bipolar I Disorder
iTBS in Bipolar I Depression
A multisite, open label pilot study to investigate the efficacy and safety of a novel accelerated intermittent theta-burst stimulation (iTBS) protocol while assessing for changes in neuroimaging biomarkers associated with…
- Trial name
- NCT05375214
- Testing
- Magnus Transcranial Magnetic Neuromodulation System (MNS) with SAINT®(Stanford Accelerated Intelligent Neuromodulation Therapy)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Major Depressive Disorder
Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder
The purpose of this study was to further characterize the efficacy, safety, and tolerability of a single fixed dose level of vilazodone compared to placebo in patients with major depressive disorder.
- Trial name
- NCT01473394
- Testing
- Vilazodone
- Where
- 14 sites in United States
- Volunteers
- 518 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Magnetic Resonance Imaging Study of Geriatric Depression
The purpose of this study was to use Magnetic Resonance Images to further our understanding of predictors and markers of treatment response and non-response in geriatric depression.
- Trial name
- NCT00245557
- Testing
- Sertraline
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Major Depressive Disorder
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy of an 8-week double-masked treatment of tasimelteon or placebo in male and female subjects with Major Depressive Disorder.
- Trial name
- MAGELLAN (NCT01428661)
- Testing
- tasimelteon
- Where
- 40 sites in United States
- Volunteers
- 507 people
- Sponsor
- Vanda Pharmaceuticals
Agitation Associated With Bipolar Disorder, Agitation,Psychomotor
Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder
This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in bipolar disorder.
- Conditions
- Agitation Associated With Bipolar Disorder, Agitation,Psychomotor, Bipolar Disorder
- Trial name
- SERENITY II (NCT04276883)
- Testing
- Sublingual film containing Dexmedetomidine (BXCL501)
- Where
- 15 sites in United States
- Volunteers
- 380 people
- Sponsor
- BioXcel Therapeutics Inc
Depression
Org 24448 to Treat Major Depression
This study will evaluate the effectiveness of the experimental drug, Org 24448, for short-term treatment of depression. It will examine the effects of the drug on symptoms, such as low mood and persistent sadness, poor sleep and…
- Trial name
- NCT00113022
- Testing
- Org 24448
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia, Schizoaffective Disorder
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Varenicline (Chantix) is a smoking cessation treatment that was approved in 2006 by the FDA for treatment of nicotine dependence and may be particularly beneficial in smokers with schizophrenia or bipolar disorder.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Smoking
- Trial name
- SCRP (NCT00621777)
- Testing
- Varenicline
- Where
- 10 sites in United States
- Volunteers
- 247 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
rTMS for Depressed Teens: A Sham-Controlled Trial, Part 1
This research proposal aims to better understand the neurobiology of depression in adolescents and how repetitive transcranial magnetic stimulation (rTMS) may therapeutically impact brain function and mood.
- Trial name
- NCT01804270
- Testing
- Repetitive transcranial magnetic stimulation (rTMS)
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Paul E. Croarkin
Major Depressive Disorder, Bipolar Disorder
Wake Therapy in the Treatment of Depression
This pilot study seeks to replicate previous findings that sleep deprivation results in marked improvement in depression symptoms, as well as to test whether concurrent treatment with Light Therapy and Lithium are successful in…
- Trial name
- NCT01431573
- Testing
- Wake Therapy, light box, Lithium
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- New York State Psychiatric Institute
Treatment Resistant Depression
Pilot Accelerated Theta Burst in Treatment-Resistant Bipolar Depression
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant bipolar depression.
- Trial name
- NCT03953417
- Testing
- Accelerated intermittent theta-burst treatment
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Stanford University
Major Depressive Disorder
A Study of LY2216684 and Digoxin in Healthy Subjects
The purpose of this study is to determine how much digoxin gets into the blood stream and how long it takes the body to get rid of it when given with LY2216684.
- Trial name
- NCT01266590
- Testing
- LY2216684, Digoxin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression
This study will compare the effect of three transcranial photobiomodulation (t-PBM) doses (high, middle, and low irradiance) to sham t-PBM on PFC CBF as assessed with fMRI (BOLD) in this multi-center, phase I, double-blinded…
- Trial name
- TRIADE (NCT04366258)
- Testing
- Transcranial Photobiomodulator
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- NYU Langone Health
Treatment Resistant Depression
Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression (SAINT-TRD)
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression.
- Trial name
- aTBS (NCT03068715)
- Testing
- Active TBS-DLPFC, Open label TBS-DLPFC
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.